GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Net Income Including Noncontrolling Interests

AN2 Therapeutics (AN2 Therapeutics) Net Income Including Noncontrolling Interests : $-64.73 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

AN2 Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was $-16.90 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was $-64.73 Mil.

AN2 Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for AN2 Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics Net Income Including Noncontrolling Interests Chart

AN2 Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
-13.60 -21.54 -40.96 -64.73

AN2 Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.84 -15.32 -15.80 -16.71 -16.90

AN2 Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AN2 Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics (AN2 Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LQDA ANAB LYEL TSHA GNLX DYN FDMT EWTX ALEC AVXL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
Website
https://www.an2therapeutics.com
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Executives
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Kabeer Aziz director 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Robin Shane Readnour director 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Kevin Michael Krause officer: Chief Strategy Officer 369 27TH STREET, SAN FRANCISCO CA 94131
Eric Easom director, officer: Chief Executive Officer 171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Joshua M Eizen officer: See Remarks 3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman director THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda officer: Chief Development Officer C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak officer: Chief Accounting Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day officer: Chief Financial Officer 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301